A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.
The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Oral presentation presented at EHA2022 describing the primary analysis of the phase 2 randomized ROSEWOOD trial: Zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refratory (R/R) follicular lymphoma (FL).
Poster presented at EHA2022 describing a phase 1 first in-human study of BGB-16673, a BTK protein degrader, in patients with B-cell malignancies (trial in progress).
Poster presented at EHA2022 describing the results from a phase 2 study of tislelizumab, a PD-1 inhibitor, for relapsed/refractory (R/R) mature T- and NK-cell neoplasms.
